The biopharmaceutical industry has seen a recovery in funding through 2026, following a prolonged downturn that limited access to capital across the sector. This recovery includes investment increasingly concentrated in later-stage, lower risk assets rather than early-stage innovation, according to GlobalData, a leading intelligence and productivity platform.
According to GlobalData’s State of the Biopharmaceutical Industry 2026 (Mid-Year Update), the most notable recovery has occurred in M&A deals, as big pharma aim to replenish their pipelines ahead of the upcoming patent cliff. The recent high-value transactions include Eli Lilly’s acquisition of Centessa Pharmaceuticals and Sun Pharmaceutical’s acquisition of Organon, valued at $7.8 billion and $11.75 billion, respectively.
A similar trend is also seen across other funding routes. The biopharmaceutical IPO market has reopened, supported by the completion of larger offerings such as Kailera Therapeutics ($718.8 million) and Generate Biomedicines ($400 million), while venture financing deals have favored later-stage rounds over early discovery and preclinical investment.
George El-Helou, Pharma Strategic Intelligence Analyst at GlobalData, comments: “Following years of market volatility, investors and acquirers have shown a clear preference for assets with reduced development risk. While the biotech funding thaw is real, allocation is hyper-selective; capital is strictly flowing to late-stage assets with clear clinical proof of concept, leaving early-stage platforms stranded in a highly constrained financing environment.”
This selectivity is most evident at the earliest stages of development where companies have fewer funding alternatives. A temporary lapse in the US SBIR/STTR program’s authorization between October 2025 and April 2026 also disrupted government grants, an important non-dilutive funding source for early stage biotechs. Although the program has since been reauthorized, the interruption added to the pressure facing this part of the sector.
El-Helou adds: “While the focus on later-stage assets is understandable, continued underinvestment in early-stage assets presents a long-term risk to the industry’s pipeline. The late-stage assets that investors are competing for rely on early-stage research that was funded years ago, and this early-stage activity must continue to be supported to enhance innovation.”
El-Helou concludes: “As the funding environment continues to recover, companies that can generate later-stage, lower-risk assets are expected to be best positioned to attract investment. Early-stage companies are increasingly turning to industry partnerships to secure the capital needed to advance their pipelines. With collaborative models now viewed as the most favored funding approach across the industry, these partnerships are likely to play a central role in sustaining early-stage innovation.”
